Auranofin

• Catalog No.: A6733
• M. F.: C20H34AuO9PS
• M. W.: 678.483871
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: [(2R,3R,4S,5R,6S)-3,4,5-tris(acetyloxy)-6-{[(triethyl-λ^5-phosphanylidene)aurio]sulfanyl}oxan-2-yl]methyl acetate
• IUPAC Traditional name: triethylphosphine gold
• Synonyms: 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium; 1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate; SKF 39162

DATABASE IDS

• MDL Number: MFCD00080759
• EC Number: 251-801-9

PROPERTIES

• Empirical Formula (Hill Notation): C20H34AuO9PS
• Purity: ≥98% (HPLC)
• Apperance: powder
• Solubility: DMSO: ≥5 mg/mL
• GHS Signal Word: Danger
• GHS Hazard statements: H301-H361
• European Hazard Symbols: Harmful (Xn)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Faceshields, Gloves
• GHS Precautionary statements: P281-P301 + P310
• RID/ADR: UN 2811 6.1/PG 3
• Risk Statements: 63-22
• RTECS: MD6500000
• Safety Statements: 36/37
• Storage Temperature: room temp
• Hazard Class: 6.1
• UN Number: 2811
• Packing Group: 3
• German water hazard class: 3

DETAILS

Description (简体中文)

Application
Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.
Biochem/physiol Actions
Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.

Description (English)

Application
Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.
Biochem/physiol Actions
Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.